IL231723A0 - Single nucleotide polymorphisms (branches) that allow predicting the response to glatiramer acetate - Google Patents
Single nucleotide polymorphisms (branches) that allow predicting the response to glatiramer acetateInfo
- Publication number
- IL231723A0 IL231723A0 IL231723A IL23172314A IL231723A0 IL 231723 A0 IL231723 A0 IL 231723A0 IL 231723 A IL231723 A IL 231723A IL 23172314 A IL23172314 A IL 23172314A IL 231723 A0 IL231723 A0 IL 231723A0
- Authority
- IL
- Israel
- Prior art keywords
- single nucleotide
- nucleotide polymorphisms
- clinical response
- glatiramer acetate
- predict clinical
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title 1
- 229960003776 glatiramer acetate Drugs 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 102000054765 polymorphisms of proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545282P | 2011-10-10 | 2011-10-10 | |
| US201261636560P | 2012-04-20 | 2012-04-20 | |
| PCT/US2012/059352 WO2013055683A1 (en) | 2011-10-10 | 2012-10-09 | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL231723A0 true IL231723A0 (en) | 2014-05-28 |
Family
ID=48082342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL231723A IL231723A0 (en) | 2011-10-10 | 2014-03-26 | Single nucleotide polymorphisms (branches) that allow predicting the response to glatiramer acetate |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8815511B2 (https=) |
| EP (1) | EP2765857A4 (https=) |
| JP (1) | JP2014530819A (https=) |
| KR (1) | KR20140101730A (https=) |
| CN (1) | CN103957705A (https=) |
| AR (1) | AR088294A1 (https=) |
| AU (1) | AU2012323345A1 (https=) |
| BR (1) | BR112014008752A2 (https=) |
| CA (1) | CA2851510A1 (https=) |
| EA (1) | EA201490749A1 (https=) |
| HK (1) | HK1200274A1 (https=) |
| IL (1) | IL231723A0 (https=) |
| MX (1) | MX2014004309A (https=) |
| TW (1) | TW201326399A (https=) |
| UY (1) | UY34380A (https=) |
| WO (1) | WO2013055683A1 (https=) |
| ZA (1) | ZA201403049B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) * | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| JP6432974B2 (ja) * | 2014-06-20 | 2018-12-05 | 国立大学法人東北大学 | ＴａｇＳＮＰの選択方法、選択用コンピュータシステム、及び、選択用ソフトウエア |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| WO2016172124A1 (en) * | 2015-04-21 | 2016-10-27 | Teva Pharmaceutical Industries Ltd. | Select single nucleotide polymorphisms predictive of response to glatiramer acetate |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| US11396825B2 (en) * | 2017-08-14 | 2022-07-26 | General Electric Company | Turbine diagnostic feature selection system |
| WO2020092753A1 (en) * | 2018-11-01 | 2020-05-07 | I2Dx, Inc. | Intelligent system and methods for therapeutic target identification |
| EP3976829A4 (en) * | 2019-05-30 | 2023-07-12 | PolygenRx Pty Ltd | METHODS OF TREATMENT OR PROPHYLAXIS |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| DK2239269T3 (da) | 1998-09-25 | 2013-04-29 | Yeda Res & Dev | Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| JP4328050B2 (ja) | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
| IL150895A0 (en) | 2000-02-18 | 2003-02-12 | Teva Pharma | Oral, nasal and pulmonary formulations of copolymer-1 |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| HUP0302333A3 (en) | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| EP1294390B1 (en) | 2000-06-07 | 2006-01-04 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| US7351686B2 (en) | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US20080293750A1 (en) | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
| US20060019269A1 (en) | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| WO2004043995A2 (en) | 2002-11-13 | 2004-05-27 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| ES2386435T3 (es) | 2003-01-07 | 2012-08-21 | Yeda Research And Development Co., Ltd. | Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica |
| RU2339397C2 (ru) | 2003-01-21 | 2008-11-27 | Йеда Рисерч Энд Дивелопмент Ко.Лтд. | Сор1 для лечения воспалительных заболеваний кишечника |
| US20070037740A1 (en) | 2003-03-04 | 2007-02-15 | Irit Pinchasi | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| WO2004103297A2 (en) | 2003-05-14 | 2004-12-02 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| US20050064483A1 (en) * | 2003-08-28 | 2005-03-24 | Baylor College Of Medicine | Gene expression profiling technology for treatment evaluation of multiple sclerosis |
| WO2005030955A1 (ja) | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
| JP2007509981A (ja) | 2003-10-31 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物デリバリー用ナノ粒子 |
| JP5456235B2 (ja) | 2003-11-12 | 2014-03-26 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経変性疾患を治療するためのワクチン及び方法 |
| US20100216863A1 (en) | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
| JP2007538003A (ja) | 2004-01-30 | 2007-12-27 | デコード ジェネティクス イーエッチエフ． | 心筋梗塞、脳卒中および末梢動脈閉塞疾患に対する感受性遺伝子、治療の方法 |
| US20050266432A1 (en) * | 2004-02-26 | 2005-12-01 | Illumina, Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
| EP1778286A4 (en) | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US20050266410A1 (en) | 2004-05-19 | 2005-12-01 | Emily Walsh | Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes |
| CN101039691B (zh) * | 2004-06-25 | 2013-07-31 | 魁北克益得生物医学公司 | 用于治疗神经疾病的组合物和方法 |
| EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| ZA200702591B (en) | 2004-09-09 | 2009-03-25 | Teva Pharma | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| AR052321A1 (es) | 2004-10-29 | 2007-03-14 | Sandoz Ag | Procesos para la preparacion de un polipeptido |
| JP2008528589A (ja) | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| WO2006089164A1 (en) | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2606194A1 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| JP2009542864A (ja) | 2006-07-05 | 2009-12-03 | モメンタ ファーマシューティカルズ インコーポレイテッド | コポリマー１の調製のための改良法 |
| US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| US7795033B2 (en) | 2007-03-19 | 2010-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods to predict the outcome of treatment with antidepressant medication |
| CA2702437C (en) | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| US20090177487A1 (en) | 2008-01-07 | 2009-07-09 | Tera Eerkes | Methods for Assessing Genetic Compatibility |
| US20110158979A1 (en) | 2008-06-13 | 2011-06-30 | Prognomix, Inc. | Genetic component of complications in type 2 diabetes |
| AU2009266947A1 (en) | 2008-07-04 | 2010-01-07 | Axial Biotech, Inc | Genetic markers associated with degenerative disc disease and uses thereof |
| EP2406396A2 (en) * | 2009-03-12 | 2012-01-18 | Brainco Biopharma, S.L. | A genotyping tool for improving the prognostic and clinical management of ms patients |
| US20120073585A1 (en) | 2009-04-08 | 2012-03-29 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| CA2697570C (en) | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| US8853378B2 (en) | 2009-10-09 | 2014-10-07 | Georgetown University | Polynucleotides that home to atherosclerotic plaque |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| AU2013361057A1 (en) | 2012-12-21 | 2015-07-30 | Teva Pharmaceutical Industries Ltd. | Oral transmucosal delivery of glatiramer acetate |
| KR20150111918A (ko) | 2012-12-21 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트의 경점막 전달 |
| MX2015008754A (es) | 2013-01-04 | 2016-04-11 | Teva Pharma | Caracterizacion de un medicamento relacionado con acetato de glatiramer. |
| US20140271630A1 (en) | 2013-03-12 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2012
- 2012-10-09 HK HK15100236.7A patent/HK1200274A1/xx unknown
- 2012-10-09 JP JP2014535787A patent/JP2014530819A/ja not_active Withdrawn
- 2012-10-09 KR KR1020147012550A patent/KR20140101730A/ko not_active Withdrawn
- 2012-10-09 AU AU2012323345A patent/AU2012323345A1/en not_active Abandoned
- 2012-10-09 CA CA2851510A patent/CA2851510A1/en not_active Abandoned
- 2012-10-09 CN CN201280058097.0A patent/CN103957705A/zh active Pending
- 2012-10-09 MX MX2014004309A patent/MX2014004309A/es unknown
- 2012-10-09 WO PCT/US2012/059352 patent/WO2013055683A1/en not_active Ceased
- 2012-10-09 TW TW101137349A patent/TW201326399A/zh unknown
- 2012-10-09 EA EA201490749A patent/EA201490749A1/ru unknown
- 2012-10-09 US US13/648,135 patent/US8815511B2/en not_active Expired - Fee Related
- 2012-10-09 EP EP12840243.5A patent/EP2765857A4/en not_active Withdrawn
- 2012-10-09 BR BR112014008752A patent/BR112014008752A2/pt not_active IP Right Cessation
- 2012-10-10 UY UY0001034380A patent/UY34380A/es not_active Application Discontinuation
- 2012-10-10 AR ARP120103778A patent/AR088294A1/es unknown
-
2014
- 2014-03-26 IL IL231723A patent/IL231723A0/en unknown
- 2014-04-25 ZA ZA2014/03049A patent/ZA201403049B/en unknown
- 2014-08-25 US US14/467,954 patent/US9499868B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014530819A (ja) | 2014-11-20 |
| US9499868B2 (en) | 2016-11-22 |
| CA2851510A1 (en) | 2013-04-18 |
| CN103957705A (zh) | 2014-07-30 |
| WO2013055683A1 (en) | 2013-04-18 |
| MX2014004309A (es) | 2015-07-06 |
| EA201490749A1 (ru) | 2014-09-30 |
| TW201326399A (zh) | 2013-07-01 |
| KR20140101730A (ko) | 2014-08-20 |
| AU2012323345A1 (en) | 2014-05-22 |
| HK1200274A1 (en) | 2015-08-07 |
| US20150045306A1 (en) | 2015-02-12 |
| ZA201403049B (en) | 2015-09-30 |
| UY34380A (es) | 2013-05-31 |
| EP2765857A1 (en) | 2014-08-20 |
| EP2765857A4 (en) | 2015-12-09 |
| US20130123189A1 (en) | 2013-05-16 |
| AR088294A1 (es) | 2014-05-21 |
| NZ624258A (en) | 2016-09-30 |
| BR112014008752A2 (pt) | 2017-04-25 |
| US8815511B2 (en) | 2014-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201403049B (en) | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate | |
| AP3584A (en) | Substituted nucleotide analogs | |
| IL227853A0 (en) | A test for detecting autoantibodies to anti-tnfα drugs | |
| IL221072A0 (en) | Single unit antibody purification | |
| ZA201400678B (en) | Alpha-amylase variants | |
| HUE056246T2 (hu) | Készítmények nukleinsav-szekvenáláshoz | |
| EP2655392A4 (en) | CYCLIC NUCLEOTID ANALOGS | |
| EP2794630A4 (en) | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE | |
| EP2686822A4 (en) | SUPPORT SYSTEM FOR CLINICAL DECISION MAKING | |
| PT3517956T (pt) | Ensaios de atividade dependente de modificação | |
| GB201118636D0 (en) | Nucleotide sequence | |
| GB201114379D0 (en) | Temperature sensor | |
| IL237744A0 (en) | Biomarkers for predicting clinical response to glatiramer acetate | |
| EP2625290A4 (en) | REAL-TIME PCR DETECTION OF INDIVIDUAL NUCLEOTIDE POLYMORPHISMS | |
| PT2627669T (pt) | Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero | |
| EP2798092A4 (en) | nucleic acid hybridization probes | |
| GB2489486B (en) | Improvements relating to construction | |
| EP2773554A4 (en) | TRETLAGER WITH TWO SPEEDS | |
| GB2479833B (en) | Modified nucleotides | |
| EP2778668A4 (en) | MULTI-REACTION BIOSENSOR | |
| GB201118026D0 (en) | Biosensor | |
| EP2594592A4 (en) | COMPLEX (NUCLEIC ACID) -POLYSACCHARIDE | |
| PL394217A1 (pl) | Beton odporny na dzialanie wysokich temperatur | |
| HK1187624A (en) | Substituted nucleotide analogs | |
| GB201110920D0 (en) | Enzyme assays |